Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR mutation

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Keytruda adds another NSCLC approval in Europe

Squamous NSCLC completes first-line dominance

AstraZeneca AZ

AZ to address Imfinzi setback, but sees potential with Tagrisso

Pharma giant to deliver oncology pipeline update at AACR

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Cancer drugs and China sustain AZ’s return to growth

Tagrisso set to become biggest seller

- PMLiVE

Neoantigen player Achilles gets OK for first clinical trial

Will test the candidate in advanced NSCLC patients

- PMLiVE

AZ’s Sean Bohen to exit after business overhaul; report

Recent departures raises concern among analysts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links